Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 12/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 11/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23335659 | 0.86 | TP53 (0.35) | TP53HPGDFABP4FABP5KDM4E | |
| SCHEMBL1856215 | 0.82 | TP53 (0.36) | TP53HPGDFABP4FABP5KDM4E | |
| SCHEMBL1854014 | 0.82 | S1PR1 (0.37) | TP53HPGDFABP4FABP5KDM4E | |
| SCHEMBL1857150 | 0.79 | TP53 (0.38) | TP53HPGDKDM4ENPC1LMNA | |
| SCHEMBL22678755 | 0.79 | FABP4 (0.41) | HPGDFABP4FABP5KDM4ENPC1 | |
| SCHEMBL1860995 | 0.77 | TP53 (0.33) | TP53HPGDKDM4ENPC1LMNA | |
| SCHEMBL23335301 | 0.73 | FABP4 (0.31) | FABP4FABP5 | |
| SCHEMBL23334742 | 0.72 | CES1 (0.38) | TP53HPGDFABP4FABP5KDM4E | |
| SCHEMBL3979426 | 0.72 | HPGD (0.62) | TP53HPGDKDM4ENPC1LMNA | |
| SCHEMBL23334741 | 0.72 | TP53 (0.57) | TP53HPGDKDM4ENPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239763-A1 | CRYSTAL FORM OF THIOPHENE DERIVATIVE AND PREPARATION METHOD THEREFOR | TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239763-A1 | CRYSTAL FORM OF THIOPHENE DERIVATIVE AND PREPARATION METHOD THEREFOR | TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20230322703-A1 | THIOPHENE DERIVATIVES AS XANTHINE OXIDASE INHIBITORS AND APPLICATION THEREOF | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
| WO-2021083319-A1 | THIOPHENE DERIVATIVES AS XANTHINE OXIDASE INHIBITORS AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-05-06 | — | — | WO | disclosed |
| WO-2021083182-A1 | URICOSURIC AGENT, SYNTHETIC METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239763-A1 | CRYSTAL FORM OF THIOPHENE DERIVATIVE AND PREPARATION METHOD THEREFOR | CYP4F11, WEE1, WEE2 | TP53 2203/4885HPGD 2481/4885FABP4 2416/4885 |
| US-20230322703-A1 | THIOPHENE DERIVATIVES AS XANTHINE OXIDASE INHIBITORS AND APPLICATION THEREOF | XDH, PNPO, TH | TP53 4754/4885HPGD 186/4885FABP4 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.